Sirona Biochem Corp (EM) (SRBCF)

More than one Product with TFC-1067 inside will be released ?

https://www.instagram.com/p/CMNe4qTFtRc/?igshid=1rff395htuivy

I heard some rumors about news before Chrismas
We will see
Go SRBCF

Waiting for news

News out !

Sirona Biochem Signs Binding Term Sheet with Cosmetic Distributor in China

Sirona Biochem: Multiple Catalysts Ahead After Breakthrough

Sirona's breakthrough with the Rodan + Fields agreement for skin lightening enables the company to focus on multiple catalysts now.

CEO Howard Verrico anticipates "multiple positive events within the next six months, hopefully much sooner".

Key catalysts are the anticipated skin lightening deal for the Chinese market and a partnership for the anti-aging / anti-wrinkle compounds.

The article discusses all known catalysts and reconfirms the investment thesis.

article on seekingalpha

Sirona Biochem: Breakthrough article !
Sirona Biochem: Breakthrough on Seeking Alpha

impressive developments of Sirona Biochem in the last few mounths ... we will see sooner than later new year highs

Sirona Biochem Signs Definitive License & Supply Agreement with Skincare Industry Leader Rodan + Fields !!

https://www.newswire.ca/news-releases/sirona-biochem-signs-definitive-license-amp-supply-agreement-with-skincare-industry-leader-rodan-fields-812383661.html

Sirona Biochem Adopts Shareholder Rights Plan

Sirona NR

The definitive agreement is expected to be signed in Q3/2019.

Q3 .. The Rodan + Fields Convention September 19-22, 2019

Sirona is pleased to announce that a non-binding term sheet has been signed with Rodan + Fields, LLC (Rodan + Fields) for the commercial sales of novel ingredient TFC-1067. This term sheet covers all material terms and conditions of a definitive agreement with San Francisco-based, industry leading, Rodan + Fields. The definitive agreement is expected to be signed in Q3/2019.

Sirona Biochem Signs Term Sheet for TFC-1067 with Skincare Industry Leader Rodan + Fields

target CAD 0.98, new Report : http://de.slideshare.net/MomentumPR/first-berlin-equity-research-sbmtsxv

new presentation out: page 29!!
http://www.sironabiochem.com/wp-content/uploads/2011/06/Sirona-Investor-Presentation-Jan-2016.pdf

Sirona Biochem Discovers Unexpected Ancillary Effects of Its Anti-Aging Compound

8:01 AM ET 5/20/15 | Marketwired

Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) is pleased to announce that its lead anti-aging compound also shows antioxidant properties in early preclinical studies.

As part of the anti-aging project, the Company has selected several potential lead compounds. One of these, SBM-TFC-837, showed a significant preservative effect against different stressors, such as starvation or ultraviolet radiation. Studies now indicate that SBM-TFC-837 also shows high preservative effect against oxidative stress induced by H2O2.

Oxidative stress response in humans causes free radicals which can damage cells and genetic material. The effect on cells can be degeneration, aging and various disease states. Antioxidants prevent this damage.

"An antioxidant effect on cells is a huge plus for our glycoprotein program for anti-aging," said Attila Hajdu, Chief Business Development Officer of Sirona Biochem. "If aging is the result of oxidative stress that leads to further cell damage, these new results suggest multiple mechanisms by which our glycoproteins exert their protective effects. This discovery will certainly be beneficial to our current partnering discussions."

Further studies are ongoing and will continue to assess cell stressors and viability. The compounds may have applications in:

View data
-- Anti-aging cosmetic product since 80% of visible aging is directly related to cell death -- Cryopreservation -- Regenerative and protective cosmetic or pharmaceutical product for healing, wound care, hypothermic protection, sunscreen, post burn / radiotherapy -- Regenerative and protective pharmaceutical product against stress response in renal reperfusion and the improvement of engraftment -- Pharmaceutical product used in organ transplantation solution (for example Wisconsin solution) -- Regenerative and preservative product for preservation of stem cells, beta-islet cells, red blood cells, adipocytes and platelets as well as tissues including reconstituted human epithelial cells, skin explants and cornea -- Preservative for vaccines

The global anti-aging market is forecast to reach up to $345.8 billion US in 2018 from $249.3 billion in 2012. The related market for regenerative medicine, which aims to restore functional ability to tissues and organs, is set to hit $67.6 billion US in 2020.

We would like to acknowledge and thank Bpifrance and the region Haute Normandie for their ongoing support on the anti-aging project

About Sirona Biochem Corp.

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona's compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona's laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information please visit www.sironabiochem.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.


For more information regarding this press release, please contact:

Christopher Hopton
CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com



SOURCE: Sirona Biochem Corp.

mailto:chopton@sironabiochem.com

Sirona Biochem to Present at BioNetwork East -- May 2015

http://www.marketwatch.com/story/sirona-biochem-to-present-at-bionetwork-east----may-2015-2015-04-13-8173214

Sirona Biochem Announces Successful Development of a Third Skin Lightener With Superior Safety and Efficacy

4:00 AM ET 3/11/15 | Marketwired

Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) announces the successful development of a third innovative skin-lightening compound that has superior safety, with zero hydroquinone release and 8 times the efficacy of deoxyarbutin. This innovation was made possible through Sirona's platform technology of fluorination chemistry and through support of the European Union and the European Regional Development Fund (E.R.D.F.).

Sirona Biochem has conducted comprehensive safety and efficacy studies in accordance with the standards of the cosmetic industry, demonstrating that SBM-TFC-1067 has the following scientifically proven properties:

View data
-- A superior safety profile over deoxyarbutin, with zero hydroquinone released in all chemical and biological tested conditions -- 8 times the efficacy of deoxyarbutin -- A high capacity to reach the site of action in the epidermis -- Additional antioxidant properties

"These results support our belief that we have developed the safest, most effective skin lightener in the world," said Attila Hajdu. "We foresee partnering this asset within a year. Our preferred partner will be a multinational corporation with a commercial infrastructure in Japan and Asia-Pacific. The valuation of this partnership will reflect the exceptional attributes of SBM-TFC-1067."

The global skin lightening market is expected to reach $20 billion USD by 2018.

As previously announced, the detailed safety and efficacy data will be presented at the Bio-Europe conference in Paris on March 11th and will be available for download on our corporate website under the Events section.

About Sirona Biochem Corp.

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona's compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona's laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information please visit www.sironabiochem.com.

About the Skin Lightening Project

Sirona Biochem's French subsidiary TFChem received a $1.9 million grant in November 2011. This project is co-financed by the European Union and Europe Witnesses in Haute-Normandie with the support of the European Regional Development Fund (E.R.D.F.). A consortium of partners, including the University of Rouen (LMSM EA4312), contract research organization Biogalenys, and TFChem has been assembled to advance this project. The French government and EU are looking to promote and initiate collaborative projects that are focused on the development of new products and services containing a high level of innovation.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.


For more information regarding this press release, please contact:

Christopher Hopton
CFO
Sirona Biochem Corp.
Phone:Â?1.604.282.6064
Email:Â?chopton@sironabiochem.com



SOURCE: Sirona Biochem Corp.

mailto:chopton@sironabiochem.com

Sirona Biochem Invited to Present at Dose of the Valley Conference, San Francisco

VANCOUVER, BC, Jan 26, 2015 (Marketwired via COMTEX) -- Sirona Biochem Corp. (SBM) (frankfurt:ZSB) announces that it has been chosen by the Consulate General of Canada to present at the Dose of the Valley conference on February 3-4 in San Francisco, California.

This unique conference will give Sirona the opportunity to showcase its platform technology and some of the latest study results to an audience of key industry players, such as: L'Oreal, Merck and Johnson & Johnson. There will also be facilitated meetings, follow up discussions and one-on-one feedback from investors, industry experts and potential partnering companies.

"Being invited to the Dose of the Valley conference is a tremendous opportunity to showcase Sirona's anti-aging and diabetes assets for leading multinational global organizations, with well-established brands in major markets," said Attila Hajdu, Chief Business Development Officer of Sirona Biochem. "The criteria for selection were evaluated on stage of development and industry validation, so we are excited to participate in such a focused event."

About Dose of the Valley

The two-day program organized by the C100 (www.thec100.org), BDC Venture Capital (www.bdc.ca) and the San Francisco Consulate is designed to connect Canada's most promising biopharma, medical device, and health IT companies with key players from within the Bay Area and Silicon Valley. Dose of the Valley will facilitate face-to-face interaction with investors, technology scouts, mentors, and industry experts. The program provides an opportunity to gain visibility and develop productive relationships within this vibrant ecosystem.

San Francisco and the Silicon Valley represent a global hub for life sciences. With a significant presence of pharmaceutical companies, health care providers, and venture capital, this region holds tremendous opportunity for Canadian companies. Applications for participation will be evaluated based on stage of development, industry validation, and relevancy to local industry interests. Elements of this program will be built to reflect the corporate objectives and therapeutic focus of participating companies.

About Sirona Biochem Corp.

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona's compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona's laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information please visit www.sironabiochem.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.


For more information regarding this press release, contact:

Christopher Hopton
CFO
Sirona Biochem Corp.
Phone:Â 1.604.282.6064
Email: chopton@sironabiochem.com



SOURCE: Sirona Biochem Corp.

mailto:chopton@sironabiochem.com

(C) 2015 Marketwire L.P. All rights reserved.

Sirona Biochem's Subsidiary TFChem Awarded Prestigious French Innovation Trophy

7:45 AM ET 12/2/14 | Marketwired

Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB), announces that its subsidiary TFChem has been awarded the 6th Haute-Normandie Innovation Trophy from SEINARI -- the Region Haute-Normandie innovation agency. TFChem founder, and Sirona's Chief Scientific Officer, Dr. GÃ?raldine Deliencourt-Godefroy, accepted the award at a ceremony held November 27th in Rouen, France.

The Company was awarded for the development and recent partnering success of an SGLT2 Inhibitor, which will be moved through clinical trials for the treatment of type 2 diabetes. The compound was developed by TFChem through the use of our novel platform technology of fluorination chemistry of carbohydrate based molecules. Parent company, Sirona Biochem, then licensed this successful innovation to Wanbang Biopharmaceuticals for the exclusive commercialization rights in China. Wanbang, as the largest diabetes specialty company in China, will continue to advance the asset through clinical trials to commercialization. This important partnership will build the foundation for expansion of the licensing agreement for commercialization rights in the rest of world, including the United States.

"It is always an honor to be recognized for the outstanding talent of our chemists as well as the work we have done partnering the diabetes compound," said Dr. Howard Verrico, CEO of Sirona Biochem. "Everyone in the company has made a tireless commitment to move our products through the pipeline and the acknowledgement of these efforts is greatly appreciated. The partnership with Wanbang Biopharmaceuticals gives us an advantage over others on the barriers to entry in China. Wanbang will know how to navigate the pathways to market and already has the trust of Chinese consumers."

China now has the largest diabetic population in the world and according to the World Health Organization (WHO), approximately 114 million Chinese people are suffering from diabetes. WHO experts project that diabetes will be the 7th leading cause of death in 2030 and China is set to remain a critical market for the foreseeable future.

About the Innovation Trophy

SEINARI (www.seinari.fr) is the innovation agency for the Northern region of Normandy France. The organization aims to foster innovation in all its forms, to accelerate the commercialization of innovative projects and support applications with members of the innovation development network.

The trophy is awarded to companies that show exemplary achievements in commercially applicable innovation projects. It is open to companies and research laboratories, and rewards recently completed projects with the aim of accelerating their commercialization. To qualify, a company must show a competitive advantage of a product or service.

About Sirona Biochem Corp.

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona's compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona's laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information please visit www.sironabiochem.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.


For more information regarding this press release, contact:

Christopher Hopton
CFO
Sirona Biochem Corp.
Phone:Â?1.604.282.6064
Email: chopton@sironabiochem.com



SOURCE: Sirona Biochem Corp.

mailto:chopton@sironabiochem.com

Sirona Biochem Names Attila Hajdu as Chief Business Development Officer

Oct 27, 2014 07:45:00 (ET)

Sirona Biochem Names Attila Hajdu as Chief Business Development Officer

VANCOUVER, BC--(Marketwired - October 27, 2014) - Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB), announces that it has named Mr. Attila Hajdu as Chief Business Development Officer. Prior to joining Sirona Biochem, Attila held various senior leadership positions within GlaxoSmithKline (GSK) and Astellas Pharma, accumulating 17 years of experience in Sales, Marketing, R&D Finance, Medical Affairs and Business Development.

"Attila Hajdu is an accomplished leader in the global pharmaceutical industry with a passion for delivering innovative solutions to optimize health outcomes. He is a skilled communicator with a solid reputation of building trusting relationships with external partners. Moreover, he is known for not only reaching set targets but exceeding expectations and bringing projects to successful conclusion. The addition of Attila to our team provides the important knowledge and experience of big pharma sales, marketing and licensing, but equally important is his solid understanding of biochemistry and keen ability to recognize the value of early stage products," said Dr. Howard Verrico, CEO of Sirona Biochem.

"It is critical that we align ourselves with the needs of our potential partners and the market to reach the next level. Having a skilled leader in business development with a proven track record is imperative and we are very confident that Attila can meet the company's needs," he added.

About Attila Hajdu

As Business Development Medical Lead for GSK, Attila was responsible for leading projects which assessed in-depth drug opportunity/risk profiles taking into account reimbursement, commercial opportunity, competition, differentiation, as well as clinical and regulatory probabilities of success. He led cross functional teams in the valuation and presentation of potential revenue generating assets to GSK's worldwide business development team. Moreover, he was supporting GSK Canada's Business Development strategy to secure new revenue generating assets.

While working for the Canadian Medical Division of GSK, Attila acquired valuable experience in the biologic therapeutic area with the anti-CD20 monoclonal antibody Arzerra for chronic lymphocytic leukemia (CLL) from concept to launch. This was accomplished by successfully engaging key stakeholders in the development of this asset through collaborative research, strategic communication, educational activities and intelligence gathering. He accomplished successful endorsement and funding of investigator driven clinical trials through leadership, influence, and negotiations with senior global executives that resulted in top tier medical journal publications and biotechnology spinoff opportunities for other compounds.

Attila played leading roles in facilitating business development opportunities, liaising with securities biotech research analysts and founding managers to explore partnership opportunities with targeted monoclonal antibody platform technologies. He scientifically engaged key external experts to deliver innovative cost effective scientific solutions, including the launch of Cervarix for cervical cancer prevention and the tyrosine kinase inhibitor Tykerb for metastatic Her 2+ breast cancer.

Attila received an MBA from Queen's University and an MSC in Biochemistry from the University of Western Ontario.

About Sirona Biochem Corp.

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona's compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona's laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information please visit www.sironabiochem.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

For more information regarding this press release, contact:

Christopher Hopton

CFO

Sirona Biochem Corp.

Phone: 1.604.282.6064

Email: chopton@sironabiochem.com

(MORE TO FOLLOW) Dow Jones Newswires

October 27, 2014 07:45 ET (11:45 GMT)

Sirona Biochem Launches Anti-Aging Preclinical Studies

7:45 AM ET 9/22/14 | Marketwire

Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) launches the next stage of development for its anti-aging compound library. With recent funding from Bpifrance (the French Public Investment Bank) and the district of Haute Normandie, Sirona Biochem's subsidiary TFChem (France) moves into the next phase of the agreement with the French laboratory Biogalenys.

Biogalenys has been chosen to work with the team of scientists at TFChem to develop the studies on the anti-aging technology. The research will provide preclinical data supporting multiple targeted applications using novel in vitro tests with varying stress conditions and cell types. The purpose is to both validate the compounds, and to satisfy the standard cohort of cosmetic safety studies. The data will then be used to determine the optimal commercial applications and joint venture partners.

"We are excited to be launching this next phase of development with Biogalenys," said Dr. Howard Verrico, CEO of Sirona Biochem. "Our two companies previously worked together successfully on the skin lightening technology and have maintained an excellent relationship of shared knowledge. The research on these anti-aging compounds is exciting from both scientific discovery and commercial opportunity prospectus."

Industry analysts predict that the anti-aging marketplace will reach nearly $285 Billion USD by the year 2018.

About Biogalenys

Biogalenys is a French laboratory (CRO) specialized in studies of transmembrane passage across several models of epithelia. Biogalenys provides, tests according to GLP or not, for active ingredients and chemical compounds and biological assays to serve the pharmaceutical and cosmetic industries. The laboratory designs the studies, conduct assays, completes data interpretation and classifies the absorption potential of drug and compounds, using different models for in-vitro, in-vivo and ex-vivo assays. Biogalenys is involved in several projects (approved by Cosmetic Valley) in research in cosmetic using efficient test with culture cells models. For more information please visit: http://www.biogalenys.com

About Sirona Biochem Corp.

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona's compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona's laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information visit www.sironabiochem.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

Image Available: http://www.marketwire.com/library/MwGo/2014/9/19/11G022181/Images/logo-RegionHN-1194462175672.jpg

Image Available: http://www.marketwire.com/library/MwGo/2014/9/19/11G022181/Images/BPI-478353289663.jpg


For more information regarding this press release, contact:
Christopher Hopton
CFO
Sirona Biochem Corp.
Phone:Â 1.604.282.6064
Email: chopton@sironabiochem.com



SOURCE: Sirona Biochem Corp.

mailto:chopton@sironabiochem.com

Sirona Biochem Announces Positive Results of PK Study for Type 2 Diabetes

VANCOUVER, BC, Sep 03, 2014 (Marketwired via COMTEX) -- Sirona Biochem Corp. (SBM) (otcqx:SRBCF) (frankfurt:ZSB) today announced that Wanbang Biopharmaceuticals has successfully completed another study in the pre-clinical validation of its anti-diabetic SGLT2 Inhibitor, SBM-TFC-039, for the treatment of Type 2 diabetes.

The pharmacokinetic (PK) study of SBM-TFC-039 confirms an excellent oral bioavailability of SBM-TFC-039. Bioavailability refers to the drug's ability to be absorbed into the body. The results are in accordance with results of an earlier study conducted by Sirona Biochem. The drug was administered as a single dose in SD rats. The first milestone of the license agreement with Wanbang Biopharmaceuticals is expected after the next scheduled study, assessing toxicology in rats during a 14 day test. This will trigger a second payment to Sirona from Wanbang Biopharmaceuticals as part of the $9.5M in upfront and milestone payments.

"These results provide further evidence that we have an excellent compound for the treatment of Type 2 diabetes," said Dr. Howard Verrico, CEO. "Good bioavailability of a drug equates to lower dosing. It's a win for us in terms of the development of our SGLT2 Inhibitor."

About Wanbang Biopharmaceuticals

Wanbang Biopharmaceuticals is the leading pharmaceutical company in China that specializes in research, production and marketing of medicines for diabetes, cardiovascular disease and endocrinology. Among domestic pharmaceutical companies, Wanbang Biopharmaceuticals is one of the largest manufacturers and marketers of a comprehensive portfolio of drugs for diabetes.

Wanbang Biopharmaceuticals is a subsidiary of Shanghai Pharmaceutical Group which is listed on the Shanghai Stock Exchange. Fosun Pharma, one of the major shareholders of Sinopharm Group, the largest drug distributor in China, is part of Fosun International, the leading non-state owned enterprise group in China which is listed on the Hong Kong Stock Exchange.

About Sirona Biochem Corp.

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona's compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona's laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information visit www.sironabiochem.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.


For more information regarding this press release, contact:
Christopher Hopton
CFO
Sirona Biochem Corp.
Phone:Â 1.604.282.6064
Email: chopton@sironabiochem.com



SOURCE: Sirona Biochem Corp.

mailto:chopton@sironabiochem.com

(C) 2014 Marketwire L.P. All rights reserved.

Sirona Biochem Launches Global Awareness Campaign With Cousteau Ambassadors' Video

Published: Aug 21, 2014 3:00 a.m. ET

VANCOUVER, BC , Aug 21, 2014 (Marketwired via COMTEX) -- Sirona Biochem Corp. (SBM) (frankfurt:ZSB) launches global awareness campaign with ambassadors' video produced by the team of Jean-Michel Cousteau and Fabien Cousteau to represent their support of the glycoprotein project.

"The time and effort put into this video illustrates just how dedicated the Cousteaus are to the relationship with Sirona Biochem," said Howard Verrico, founder and CEO. "Having Jean-Michel and Fabien's support for this project serves as a reminder of the immense potential value in these compounds."

Jean-Michel Cousteau and Fabien Cousteau (son and grandson of Jacques Cousteau) are brand ambassadors for Sirona's glycoprotein project. The project has also been generously supported by Bpifrance (the French Public Investment Bank) and the district of Haute Normandie with funding of CDN$1.2 million in the form of a no-interest loan.

The video can be viewed at the following link: (with German subtitles: )

Sirona Biochem also announces attendance at the upcoming BIO Europe conference in Frankfurt Germany Nov 3-5 2014 with support from BIOTECanada and the Canadian Trade Commissioner Service, Global Opportunities for Associations (GOA) program.

About Sirona Biochem Corp.

Sirona Biochem is a biotechnology company developing diabetes therapeutics, skin depigmenting and anti-aging agents for cosmetic use, biological ingredients and cancer vaccine antigens. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules. Sirona Biochem is the parent company of French-based biotechnology company, TFChem. For more information visit www.sironabiochem.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

FOR FURTHER INFORMATION PLEASE CONTACT:

For more information regarding this press release, contact:

Christopher Hopton CFO Sirona Biochem Corp. Phone: 604.282.6064 Email: chopton@sironabiochem.com

SOURCE: Sirona Biochem Corp.

© 2014 Marketwire L.P. All rights reserved.

Sirona Subsidiary, TFChem, Receives CDN$1.2 Million for Anti-Aging Project

7:45 AM ET 8/12/14 | Marketwire

Sirona Biochem Corp. (TSX VENTURE: SBM) (OTCQX: SRBCF) (FRANKFURT: ZSB), (the "Company") announced that its French subsidiary, TFChem, has received confirmation for funding of CDN$1.2 million from Bpifrance (the French Public Investment Bank) and the district of Haute Normandie in the form of a no-interest loan. The funds will be used to advance the organization's anti-aging project.

The loan, co-funded by Bpifrance and the district of Haute Normandie, will be dispersed in lump sums and is strictly allocated for advancement of the anti-aging compounds into preclinical testing. Repayment of the loan will be made in installments, beginning in Q3 2018 with the majority being paid after 2020. The company expects to be into substantial milestone and royalty payments before any repayment of the loan begins.

"With the tremendous support provided by this loan the need to arrange financings over the next 12 to 18 months are anticipated to be minimal," reports CEO and Chairman of Sirona Biochem, Dr. Howard Verrico. "The funding received from Bpifrance and the district of Haute Normandie will enable us to start testing our library of anti-aging compounds without dilution. We are very excited about the potential of these compounds and the interest shown in them."

The global anti-aging product market is currently valued at over $220 Billion USD with a CAGR of 5.2%. It's expected to be nearly $285 Billion USD by the year 2018.(1)

About Sirona Biochem and TFChem

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds' efficacy and safety. Sirona Biochem's compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem's wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com or www.tfchemistry.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

(1) http://www.marketwatch.com/story/antiaging-products-and-services- the-global-market-2013-08-19


For more information regarding this press release, contact:
Christopher Hopton
CFO
Sirona Biochem Corp.
Phone:Â 1.604.282.6064
Email: chopton@sironabiochem.com



SOURCE: Sirona Biochem Corp.

mailto:chopton@sironabiochem.com

a real interesting read!!!

for translation google or bing ( like we german often do it )

___________________________________________________________________

http://www.sharedeals.de/2014/08/05/sirona-biochem-das-biotech-juwel-des-jahres/


___________________________________________________________________

Sirona Biochem Announces Successful Synthesis of Anti-Inflammatory Compound for Bloom Burton & Co. Joint Venture

7:45 AM ET 7/31/14 | Marketwire

Sirona Biochem Corp. (TSX VENTURE: SBM) (OTCQX: SRBCF) (FRANKFURT: ZSB), (the "Company") announces the achievement of the first batch of compound in the joint venture with Bloom Burton & Co. ("Bloom Burton") Compounds developed within the framework of the JV will be entering development in the areas of rare inflammatory and infectious diseases.

At present, there are unmet market needs in the areas of rare or neglected inflammatory diseases and bacterial resistance. Sirona and Bloom Burton are identifying and designing a library of compounds to address these substantial markets which combined reach nearly $2 Billion US each year globally. Sirona is responsible for the chemistry and Bloom Burton for the financing, clinical validation as well as the commercialization of the compounds.

"We could not be more pleased with the completion of the first synthetic compounds. This is a major milestone in the development of our portfolio for rare and neglected diseases," said Howard Verrico, CEO of Sirona Biochem. "The team at Bloom Burton will plan for the testing of our new anti-inflammatory compounds in the near future. In the next several months, we will be working on the development of further compounds for our JV with Bloom Burton as planned."

About Bloom Burton & Co.

Bloom Burton & Co. exists to accelerate monetization in healthcare. Bloom Burton has an experienced team of medical, scientific, pharmaceutical, legal and capital markets professionals who perform a deeper level of diligence, which combined with a creative and entrepreneurial culture, leads to the right monetizing events for companies and investors. Bloom Burton's many services include capital raising, mergers and acquisitions advisory, equity research, scientific and medical consulting, direct investing, company creation and incubation. For more information, please visit www.bloomburton.com.

About Sirona Biochem

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds' efficacy and safety. Sirona Biochem's compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem's wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


For more information regarding this press release, contact:
Christopher Hopton
CFO
Sirona Biochem Corp.
Phone:Â 1.604.282.6064
Email: chopton@sironabiochem.com



SOURCE: Sirona Biochem Corp.

mailto:chopton@sironabiochem.com

Sirona Biochem Announces Successful Completion of Two First Line Studies by Wanbang Biopharmaceuticals

Jul 23, 2014 07:45:00 (ET)

Sirona Biochem Announces Successful Completion of Two First Line Studies by Wanbang Biopharmaceuticals

VANCOUVER, BC--(Marketwired - July 23, 2014) - Sirona Biochem Corp. (TSX VENTURE: SBM)(OTCQX: SRBCF)(FRANKFURT: ZSB) (the "Company") today announced that Wanbang Biopharmaceuticals has completed two pre-clinical efficacy studies of its SGLT2 inhibitor SBM-TFC-039. The studies independently confirm that SBM-TFC-039 increased Urinary Glucose Excretion and improved Oral Glucose Tolerance in normal SD rats. The results were consistent with those previously completed by Sirona Biochem.

The next steps in the validation of SBM-TFC-039 will be the Pharmacokinetic study and the 14 day toxicology repeated administration on normal SD rats. If further positive results are obtained, as expected, Wanbang will have completed the first milestone of its license agreement with Sirona Biochem. This will trigger a second payment to Sirona from Wanbang Biopharmaceuticals, part of the $9.5M in upfront and milestone payments.

According to a 2013 study* published in The Journal of the American Medical Association the People's Republic of China now has the greatest prevalence of diabetes. It is estimated that 11.6% of the adult population or 114 million people are affected; this is the first time that a country has surpassed the United States, which has an estimated 11.3% living with the disease.

It is also estimated that approximately half of all Chinese adults, a total of 493 million people, could be suffering from pre-diabetes, a preliminary stage in which the sugar metabolism is already disturbed, but diabetes is not yet present.

"Wanbang Biopharmaceuticals dedication to quickly advancing this project to clinical trials confirms the strength of Sirona's partnership with China's top ranked diabetes pharmaceutical company. The value of this pharmaceutical to Sirona grows both within China, home of the world's largest Diabetic population and outside China to other potential pharmaceutical partners," said Howard Verrico, Chief Executive Officer of Sirona Biochem.

* http://jama.jamanetwork.com/article.aspx?articleid=1734701

About Wanbang Biopharmaceuticals

Wanbang Biopharmaceuticals is a leading pharmaceutical company in the People's Republic of China that specializes in research, production and marketing of medicines for diabetes, cardiovascular disease and endocrinology. Among domestic pharmaceutical companies, Wanbang Biopharmaceuticals is one of the largest manufacturers and marketers of a comprehensive portfolio of drugs for diabetes.

Wanbang Biopharmaceuticals is a subsidiary of Shanghai Pharmaceutical Group which is listed on the Shanghai Stock Exchange. Fosun Pharma, one of the major shareholders of Sinopharm Group, the largest drug distributor in China, is part of Fosun International, the leading non-state owned enterprise group in China which is listed on the Hong Kong Stock Exchange.

About Sirona Biochem

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds' efficacy and safety. Sirona Biochem's compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem's wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

For more information regarding this press release, contact:

Christopher Hopton

CFO

Sirona Biochem Corp.

Phone: 1.604.282.6064

Email: chopton@sironabiochem.com

(MORE TO FOLLOW) Dow Jones Newswires

July 23, 2014 07:45 ET (11:45 GMT)

Sirona Announces Shares for Services Agreement

VANCOUVER, BC, Jul 22, 2014 (Marketwired via COMTEX) -- Sirona Biochem Corp. CA:SBM +11.11% (otcqx:SRBCF) (frankfurt:ZSB), (the "Company") is pleased to announce that it has entered into a business consulting agreement (the "Agreement") with PRC Partners Ltd. of Hong Kong ("PRC"), for a six month term commencing July 15, 2014.

As compensation for the services to be provided, PRC will receive a total of 1,500,000 common shares of the Company, in tranches of 250,000 common shares each, on a monthly basis starting August 15, 2014. PRC will also receive stock options in the Company, under the Company's stock option plan, entitling it to purchase 500,000 common shares at a price of $0.15 per share and 500,000 common shares at a price of $0.20 per share expiring 60 days after the Agreement is terminated.

Services to be provided by PRC include consultation, advice, and the arrangement of strategic relationships with other companies and the acquisition of projects, access to capital markets in Europe, and similar activities designed to further the business and development of the Company.

The Agreement and all securities proposed to be issued thereunder are subject to the acceptance of the TSX Venture Exchange.

About PRC Partners

PRC Partners is a Hong Kong-based corporate development consulting firm owned Frank Haentjes. Mr. Haentjes is a native of Cologne, Germany, raised and educated in Brazil, Germany and the United States. He has been living and working in China for much of the last decade, successfully assisting Canadian public companies in tapping investment funds from State-owned Enterprises and high-net-worth individuals.

PRC Partners has a self-professed focus on the discovery of undervalued and promising growth companies, and serves these companies by increasing visibility and accessing capital through an experienced network of investors.

Due to the increasing demand from his investors, Mr. Haentjes has taken a strong interest in technology as well as in biotech/healthcare deals that are either public or about to go public. He has extensive relationships in Asia, Europe and the Middle East. He will be providing the services on behalf of PRC Partners.

About Sirona Biochem

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds' efficacy and safety. Sirona Biochem's compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem's wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com .

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.









For more information regarding this press release, contact:
Christopher Hopton
CFO
Sirona Biochem Corp.
Phone:Â 1.604.282.6064
Email: chopton@sironabiochem.com





SOURCE: Sirona Biochem Corp.

Sirona Biochem Corporation - CEO Letter to Shareholders

Jul 21, 2014 10:26:00 (ET)

Sirona Biochem Corporation - CEO Letter to Shareholders

VANCOUVER, BC--(Marketwired - July 21, 2014) - Sirona Biochem Corp. (TSX VENTURE: SBM) (OTCQX: SRBCF) (FRANKFURT: ZSB) today provided a business update.

Dear Shareholders and Investors,

As announced in our recent news release, I, Howard Verrico, have stepped in as CEO of Sirona Biochem. Although this change is significant, I have always maintained an active role in Sirona's operations throughout its history making this an efficient transition. I can assure you we are moving along on all initiatives as planned. As founder, Chairman of the Board and a major shareholder I will personally ensure the responsibilities and deliverables of CEO are achieved. Under supervision of Sirona's Board, the search, selection and appointment of a new executive management team member will occur as a priority task.

Financial:

In February 2014, we announced the completion of a $1.2M private placement. The original plan was to follow this up with a US led investment of approximately $4 million. This initiative was abandoned since terms did not meet our vision for the direction of our company. The management of the company was and is unwilling to settle for terms that we feel create risk to the current shareholder value.

We anticipate minimal financing needs over the next twelve to eighteen months. To avoid unnecessary dilution, we will continue to apply for government grants and loans where applicable rather than pursue an equity raise. Moreover, we are expecting further substantial milestone payments as well as initial royalty payments.

Our current institutional investors remain very supportive of our future growth strategy. We have recently been encouraged by strong interest from European investors which could bode very well for us going forward. In addition to that, we plan to further increase market awareness for Sirona in the next several months.

Strategy:

Sirona Biochem remains committed to a streamlined business strategy of chemistry, patent and license.

Our expertise remains in creating new chemical compounds (pharmaceutical and cosmetic) that have distinct advantages over existing technologies. Each compound that we create will be licensed to an industry-leading company who will be responsible for developing, manufacturing and selling the compound. In return, Sirona will receive licensing fees, milestone payments and ongoing royalty payments.

Through our platform technology, we have been able to diversify our risk across multiple projects, increase our portfolio size more quickly and continue to build our credibility and reputation as experts in the discovery of innovative therapeutics.

The Board of Directors is taking an increasingly active role in refining the company strategy and how it is implemented. Our Board has a diverse and valuable skill set which we are utilizing to the fullest extent.

Operations:

In March, we bolstered our France team with the addition of Claude Nivet. Claude's official title is Laboratory Manager. This role was developed specifically to assist in growing operations and relieving our Chief Scientific Officer, Geraldine Deliencourt-Godefroy, of some of her non-scientific tasks. This will allow her to focus on innovation and management of the current pipeline.

Our current R&D focus is on the following:

-- Assist Obagi/Valeant in the manufacturing and monetization of our skin
lightener. Obagi/Valeant will be responsible for the formulation and
sales of the compound;

-- Develop the anti-aging library of compounds in anticipation of government
funding and commencement of pre-clinical studies;

-- Synthesize the anti-inflammatory compound for our Bloom Burton
partnership.
As projects progress and resources become available, we will explore new areas where our technology will add significant value.

Current Business Development:

-- At the end of April 2014, Wanbang Biopharmaceuticals began pre-clinical
validation for Sirona Biochem's second generation SGLT2 Inhibitor. To
date, Sirona has received Wanbang's initial licensing fee and the Chinese
government's innovation tax application has been approved. Wanbang has
successfully hired an expert in pharmacology and toxicity to lead the
project and compound synthesis has begun to ensure quantities of the
compound will be available for all future clinical trials. Further
updates from Wanbang will become available shortly.

-- Obagi Medical Products is moving forward on Sirona Biochem's skin
lightening compound TFC-849. Obagi Medical Products is responsible for
all development, manufacturing and sales of the compound and in return
Sirona Biochem will receive licensing and milestone fees and ongoing
royalty payments.

-- Our Joint Venture with Bloom Burton and Co. is progressing nicely. Once
the first compound is synthesized, it will enter early stage testing.
Bloom Burton is Canada's largest and most active healthcare-specialized
investment banking firm. The goal of this joint venture is to conduct
collaborative research to develop and commercialize new therapeutics in
the areas of inflammation and infectious disease.

-- Sirona's Chief Scientific Officer recently attended industry meetings in
New York City. The meetings were very successful and have generated
multiple potential partnerships. We will provide updates regarding these
opportunities on the next shareholder letter. Although we have a number
of significant partnering initiatives fully executed and underway, we are
continuing to explore new partnership opportunities and currently have
multiple ongoing conversations with large Pharma and cosmetic companies
around the world.
Our goal has always been for Sirona Biochem to become the global leader in the process of compound stabilization which leads to unlimited applications in pharmaceuticals and cosmetics. The value of Sirona Biochem lies in its technology and we intend to put our resources behind this. At the end of the day, our common goal is to create shareholder value which is exactly what we work to accomplish every single day. Sirona is well positioned to take advantage of some of the major opportunities that are available to us and we are working diligently to take our company to the next level.

I sincerely appreciate the past support of our shareholders and ask for your future support as we move forward.

Best Regards,

Dr. Howard Verrico

CEO, Chairman of the Board

Sirona Biochem

About Sirona Biochem Corp.

Sirona Biochem is not a traditional biotech company. Sirona is a product-pipeline company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds' efficacy and safety. Sirona Biochem's compounds are being developed for both pharmaceutical and cosmetic marketplaces and are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem's wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information please visit www.sironabiochem.com.

For more information regarding this press release, contact:

Christopher Hopton

CFO

Sirona Biochem Corp.

Phone: 1.604.282.6064

Email: chopton@sironabiochem.com

(MORE TO FOLLOW) Dow Jones Newswires

July 21, 2014 10:26 ET (14:26 GMT)

Sirona Biochem CEO Neil Belenkie resigns



By Emma Crawford Hampel
Tue Jun 24, 2014 9:23am PST
Sirona Biochem Corp. president Neil Belenkie is resigning from his position as CEO, the company announced June 23.

Sirona’s CFO Christopher Hopton told Business in Vancouver that Belenkie decided to resign because as the company has evolved, its needs changed.

“He felt he was no longer a good fit,” Hopton said

Belenkie will remain with the company until July 18. An executive search is on for Belenkie’s replacement, said Hopton.

Howard Verrico, Sirona’s founder and chairman, will act as interim CEO.

Belenkie has been CEO of Sirona Biochem since October 2012. He is also the CEO and co-founder of the GrowthPoint Group and an alumnus of Harvard, Queen’s, the University of Calgary and Mount Royal University.

Belenkie was a winner of Business in Vancouver’s Forty under 40 in 2011.

ecrawford@biv.com

@EmmaHampelBIV

Sirona Biochem's Subsidiary, TFChem, Selected for UBISTART Tour 2014

Jun 11, 2014 07:45:00 (ET)

Sirona Biochem's Subsidiary, TFChem, Selected for UBISTART Tour 2014

VANCOUVER, BC--(Marketwired - June 11, 2014) - Sirona Biochem Corp. (TSX VENTURE: SBM) (OTCQX: SRBCF) (FRANKFURT: ZSB) is pleased to announce that its subsidiary, TFChem, has been selected for participation in the UBISTART Tour July 10-11, 2014 at the New York Academy of Sciences, New York City, New York USA. The UBISTART Tour, which combines innovation and scientific excellence in life sciences, encourages and rewards international partnerships between French and North American innovators within the pharmaceutical, biotechnology, medical technology, and healthcare industries. An international jury under the auspices of the Galien Foundation Board was responsible for the selection of TFChem and other French participants to the UBISTART Tour.

"Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research," comments Neil Belenkie, CEO of Sirona Biochem. "We are extremely proud to be recognized for inclusion in the UBISTART Tour by globally respected organizations such as the Galien Foundation and UBIFRANCE."

About The UBISTART Program

On July 10, during the UBISTART Tour, the selected participating companies will have the opportunity to present their project(s), to learn about the projects of other companies and to meet with potential partners (either from companies or other individuals in the program).

The partnerships that arise from the UBISTART Tour will then have three months to develop and present their international project and apply to the UBISTART competition. The Galien Foundation Board, which includes several Nobel Laureates, will oversee the selection of the independent international jury who will be responsible each December for choosing and awarding the UBISTART Award to the most innovative and promising of the projects originating from the UBISTART Tour.

http://ubistarttour.galienfoundation.org/index.php

About The Galien Foundation

The Galien Foundation fosters, recognizes and rewards excellence in scientific innovation to improve the state of human health. Our vision is to be the catalyst for the development of the next generation of innovative treatment and technologies that will impact human health and save lives.

The Foundation oversees and directs activities in the USA for the Prix Galien, an international award that recognizes outstanding achievements in improving the human condition through the development of innovative therapies. The Prix Galien was created in 1970 in honor of Galen, the father of medical science and modern pharmacology. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research.

http://www.galienfoundation.org/

About UBIFRANCE

UBIFRANCE, the French Agency for International Business Development comes under the aegis of France's Ministry for the Economy, Finance & Industry.

UBIFRANCE promotes technologies, products, services and know-how from France, and puts French-based professionals in contact with their international counterparts.

http://www.ubifrance.com/

About Sirona Biochem

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona's compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona's laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information visit www.sironabiochem.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

For more information regarding this press release, contact:

Christopher Hopton

CFO

Sirona Biochem Corp.

Phone: 1.604.282.6064

Email: chopton@sironabiochem.com

(MORE TO FOLLOW) Dow Jones Newswires

June 11, 2014 07:45 ET (11:45 GMT)

Sirona Biochem Announces Wanbang Biopharmaceutical's Launch of Pre-Clinical Validation

Jun 03, 2014 07:45:00 (ET)

Sirona Biochem Announces Wanbang Biopharmaceutical's Launch of Pre-Clinical Validation

VANCOUVER, BC--(Marketwired - June 03, 2014) - Sirona Biochem Corp. (TSX VENTURE: SBM) (OTCQX: SRBCF) (FRANKFURT: ZSB) announces that Licensee Wanbang Biopharmaceuticals (Wanbang) has begun pre-clinical validation for Sirona Biochem's second generation SGLT2 Inhibitor. To date, Sirona has received Wanbang's licensing fee, the Chinese government's innovation tax application has been approved, Wanbang has successfully hired an expert in pharmacology and toxicity to lead the project and compound synthesis has begun to ensure quantities of the compound will be available for all future clinical trials.

About the License Agreement with Wanbang Biopharmaceuticals

Wanbang Biopharmaceuticals secured the exclusive rights to sell Sirona Biochem's SGLT2 Inhibitor in the People's Republic of China for US$9.5M in upfront and milestone payments with ongoing royalty payments as a percentage of all sales. Wanbang is responsible for funding and managing all clinical validation for the diabetes drug, removing the financial and resource burden for the development of the second generation SGLT2 Inhibitor from Sirona Biochem.

Sirona Biochem will oversee and contribute to the design and execution of all clinical studies and will receive all data generated by Wanbang. Following the successful completion of each study, Sirona will receive a milestone payment from Wanbang and the global value of Sirona's SGLT2 Inhibitor will rise significantly. Sirona has the option of licensing its SGLT2 Inhibitor to the rest of the world at any time; previous transaction values for the first generation of SGLT2 Inhibitors globally include:

-- Empagliflozin, one of a two-compound licensing deal between Boehringer
Ingelheim and Eli Lilly for at one time payment of EUR300 million and
milestone payments of EUR625 million.

-- Dapagliflozin (Forxiga(R)), one of a two-compound licensing deal between
Bristol Myers Squibb and AstraZeneca for upfront payment of US$100
million and milestone payments of up to US$1.25 billion

-- Bristol Myers Squibb and AstraZeneca expand licensing deal of
Dapagliflozin to include Japan; deal estimated to bring more than US$1
billion
About Wanbang Biopharmaceuticals

Wanbang Biopharmaceuticals is a leading pharmaceutical company in China that specializes in research, production and marketing of medicines for diabetes, cardiovascular disease and endocrinology. Among domestic pharmaceutical companies, Wanbang Biopharmaceuticals is one of the largest manufacturers and marketers of a comprehensive portfolio of drugs for diabetes.

Wanbang Pharma is a subsidiary of Fosun Pharmaceutical Group which is listed on the Shanghai stock exchange. Fosun Pharma, one of the major shareholders of Sino Pharma, the largest drug distributor in China, is part of the Fosun Group, the leading non-state owned enterprise group in China which is listed on the Hong Kong stock exchange.

About Sirona Biochem

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona's compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona's laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information visit www.sironabiochem.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

For more information regarding this press release, contact:

Christopher Hopton

CFO

Sirona Biochem Corp.

Phone: 1.604.282.6064

Email: chopton@sironabiochem.com

(MORE TO FOLLOW) Dow Jones Newswires

June 03, 2014 07:45 ET (11:45 GMT)

Sirona Biochem Expands Exclusive Skin Lightening License With Valeant Pharmaceuticals to Include AMBI and Kinerase

May 29, 2014 07:45:00 (ET)

Sirona Biochem Expands Exclusive Skin Lightening License With Valeant Pharmaceuticals to Include AMBI and Kinerase

VANCOUVER, BC--(Marketwired - May 29, 2014) - Sirona Biochem Corp. (TSX VENTURE: SBM) (OTCQX: SRBCF) (FRANKFURT: ZSB) announces the expansion of its exclusive license with Valeant Pharmaceuticals ("Valeant") for Sirona's skin lightening compound TFC-849 to include AMBI and Kinerase. Under the terms of the licensing agreement, Valeant has the exclusive global rights to TFC-849 for use throughout its international portfolio of companies and brands. AMBI and Kinerase, along with Obagi Medical Products (see press release dated January 29, 2014), are part of Valeant's diverse portfolio focused primarily on dermatology.

"We are excited to add AMBI and Kinerase, two of Valeant Pharmaceutical's premium skin care companies, to the commercial license for TFC-849," commented Mr. Neil Belenkie, CEO of Sirona Biochem. "Adding premium brands with global distribution through over-the-counter (OTC) store sales and significant ecommerce platforms ensures that our compound will reach leading skin lightening and brightening markets around the world."

The global skin lightening market is projected to reach approximately $20 billion by 2018, representing one of the fastest growing segments within the global beauty industry. Sirona has created and patented a skin lightening active ingredient which is up to 14 times more effective than Arbutin, one of the world's leading skin lightening compounds. Most importantly, Sirona's compound is 100% safe and can be sold everywhere in the world.

About AMBI

AMBI(R), the leading mass brand for African Americans, enables women of color to achieve flawless beauty by offering skincare products exclusively designed for melanin-rich skin. AMBI((R)) Skincare is one of the brands under Valeant Pharmaceuticals North America. AMBI, a trusted name in cleansers and moisturizers for skin of color, has a legacy of skin care designed to provide smooth, even-toned, flawless-looking skin. Introduced in 1966, the brand has been used and trusted by women with richer skin tones for decades to provide quality products that meet skin of color needs. The AMBI(R) Brand is best known for its fade creams, which help fade dark spots and skin discolorations to restore flawless, natural skin tone.

About Kinerase

Kinerase(R) skincare was developed over 20 years ago by Valeant to address anti-aging skin care concerns. Kinerase provides powerful results, gently. Its biotechnical formulation is supported by kinetin, a plant-based antioxidant with properties that were discovered when scientists found that it prevented plant leaves from drying out and withering. This same technology is the foundation on which the entire Kinerase line was built. Kinetin reaches cells deep within the skin to keep it smooth and radiant. Indulge in the luxury of skincare science to reveal your most beautiful and youthful looking skin.

About Sirona Biochem

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona's compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona's laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information visit www.sironabiochem.com.

About the Betaclear (Skin Lightening) Project

Sirona Biochem's French subsidiary TFChem received a $1.9 million grant in November 2011. This project is co-financed by the European Union and Europe Witnesses in Haute-Normandie with the support of the European Regional Development Fund (E.R.D.F.). A consortium of partners, including the University of Rouen (LMSM EA4312), contract research organization Biogalenys, and TFChem has been assembled to advance this project. The French government and European Union are looking to promote and initiate collaborative projects that are focused on the development of new products and services containing a high level of innovation.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

For more information regarding this press release, contact:

Christopher Hopton

CFO

Sirona Biochem Corp.

Phone: 1.604.282.6064

Email: chopton@sironabiochem.com

(MORE TO FOLLOW) Dow Jones Newswires

May 29, 2014 07:45 ET (11:45 GMT)

hold 2oo k Shares in Canada, http://web.tmxmoney.com/quote.php?qm_symbol=SBM

Sirona's Science Boosts Anti-Aging Technology

May 26, 2014 13:37:00 (ET)

Sirona's Science Boosts Anti-Aging Technology

VANCOUVER, British Columbia, May 26, 2014 (GLOBE NEWSWIRE) -- Within the town of Val de Reuil in the French coastal province of Normandy at a place called the Path of Innovations, scientists are working to slow down the human body's aging process.

The TF Chem lab owned by Vancouver's Sirona Biochem Corp. (TSX-V:SBM), is in the forefront of a race where promising anti-aging technology is being developed based on the findings of animal biology professor, Arthur DeVries.

DeVries discovered that Antarctic fish were able to survive sub-zero temperatures under the polar icecaps thanks to glycoproteins or an "anti-freeze" that protect their cells.

Sirona and its subsidiary TFChem have now successfully synthesized compounds derived from these naturally occurring glycoproteins and created an anti-aging technology intended to protect people's skin, not just from cold temperatures, but UV damage, oxidative stress and other catalysts of visible aging.

The discovery is so significant in the biotech sector that it did not take long for the Cincinnati Children's Hospital Medical Center to formalize an agreement with Sirona to use each other's technology to create an anti-aging skin care treatment.

"Our shared goal is to create an anti-aging skin treatment that presents unparalleled efficacy and commercial opportunity for the predicted $300 billion dollar anti-aging global market," said Neil Belenkie, CEO of Sirona Biochem.

Sirona's anti-aging project is also being championed by Jacques Cousteau's son and grandson, Jean-Michel and Fabien Cousteau, who will lend their global brand to support the commercialization of this new anti-aging cosmetic technology, especially because it does not require harvesting any fish.

It has also attracted unwanted attention by multi-national cosmetic giants like L'oreal which see the potential of synthetic protein's promising anti-aging properties to develop its own product.

"It's a demonstration of how valuable this technology is being perceived by the industry and how competitive an industry it is," said Belenkie.

Sirona, with a modest market cap of $12.2 million, is one of the bright lights in the biotech industry which has recently taken a stock market beating after a two year tear.

Biotech market analysts believe that Sirona's science is incredibly promising for investors looking for serious growth because of its diverse programs.

In addition to the anti-aging program developed by TFChem, the scientists at Sirona's French lab are also world renowned in the stabilization of carbohydrate molecules.

Sirona Biochem's proprietary chemistry technology has relevance in many therapeutic, cosmetic and biological areas where the potential for development is high. In addition to the diabetes, skin lightener, anti-aging and biological ingredients programs, the company is exploring development of a cancer vaccine antigen.

With some products fairly close to marketability and others showing multiple uses in the pipeline, Sirona has signed an agreement with Bloom Burton, Canada's leading healthcare-specialized investment banking group, to commercialize new therapeutics in the areas of inflammation and infectious disease.

"We believe Sirona has more therapeutic opportunities than can be exploited by Sirona alone. We are excited to develop these assets in partnership with Sirona and monetize them at the appropriate time," said Bloom Burton President, Brian Bloom.

Last January, Sirona entered into a global exclusive licensing agreement with Obagi Medical Products (Obagi), a subsidiary of Valeant Pharmaceuticals, for the commercialization of its skin lightening compound TFC-849. Obagi Medical Products, Inc. is a global specialty pharmaceutical company specializing in products that are designed to minimize the appearance of premature skin aging, skin damage, hyperpigmentation, acne, and sun damage.

In the same month, Sirona completed an exclusive licensing agreement with Wanbang Biopharmaceuticals (Wanbang Biopharma) for its anti-diabetic SGLT2 inhibitor in the People's Republic of China.

Wanbang Biopharma is one of the largest manufacturers and marketers of a comprehensive portfolio of drugs for diabetes in China where, more than 90 million people suffer from diabetes, and this number is increasing at an alarming rate of 20% per year.

Paul Drohan, president and CEO of LifeSciences BC, a Vancouver-based industry association, said today's environment is an interesting one for the biotech industry in Canada and globally. "It's a really unique time. We're starting to see capital coming back, and some unique agreements being signed with international organizations. Sirona, for one, has established a foothold in China, as well as Europe where government is very supportive of the life sciences industry."

http://business.financialpost.com/2014/05/22/sironas-science-boosts-anti-aging-technology/

CONTACT: Christopher Hopton
CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
(MORE TO FOLLOW) Dow Jones Newswires

May 26, 2014 13:37 ET (17:37 GMT)

Sirona Biochem's Anti-Aging Glycoprotein Successfully Extends Cell Life in Serum Deprivation Study

May 20, 2014 07:45:00 (ET)

Sirona Biochem's Anti-Aging Glycoprotein Successfully Extends Cell Life in Serum Deprivation Study

VANCOUVER, BC--(Marketwired - May 20, 2014) - Sirona Biochem Corp. (TSX VENTURE: SBM) (OTCQX: SRBCF) (FRANKFURT: ZSB) announces its anti-aging compound TFC-837 was proven to extend cell life with outstanding results in a 12-day serum-deprivation study. The study subjected unprotected and glycoprotein-protected fibroblast cells to a serum-deprived environment for a period of twelve days. By day ten of the study, 100% of the unprotected cells were dead. In contrast, 75% of the glycoprotein-protected cells continued to be fully viable at the conclusion of the twelve day study.

"We couldn't be more excited by these results and the potential value these compounds can create," commented Mr. Neil Belenkie, CEO of Sirona Biochem. "Results such as these are the reason we have attracted globally respected partners for this project, including Jean-Michel Cousteau, Fabien Cousteau and the Cincinnati Children's Hospital Medical Center. This is absolutely groundbreaking technology; the first in a new family of synthetic glycoproteins successfully created and patented by our scientific team."

Next steps for the development of this compound include additional studies to validate other cell preservation qualities and the standard cohort of cosmetic safety studies necessary for launch of this compound as an anti-aging ingredient. The goal for this compound is to be available for acquisition by a global partner within six months. Desired terms for an exclusive license will be the same as the terms secured in the global exclusive license with Obagi Medical Products (subsidiary of Valeant Pharmaceuticals); licensing fee, milestone fee, and an ongoing royalty payment structure with minimum sales revenue requirements.

Targeted Applications for this New Family of Compounds

Early data supports targeted applications including the following:

-- Cosmetic (no FDA approval required, inexpensive studies, quick to market)

-- Anti-aging cream (global marketplace, $300 billion in annual
sales)
-- Pharmaceutical

-- Extend platelet storage beyond current 4-5 day limitation

-- Improve outcomes for beta-islet cell transplants

-- Improve stem cell storage solution versus conventional mediums

-- Improve organ transplantation donor-to-recipient windows

-- Protect against harmful UV or radiation
Project Background

In 1969, an antifreeze glycoprotein was discovered in fish living under the Antarctic icecaps. The discovery was groundbreaking because this specific glycoprotein enabled the Antarctic fish to survive (and not freeze solid) in the subzero temperatures.

Sirona Biochem's subsidiary, TFChem (France) has synthesized and stabilized its derivative of this antifreeze glycoprotein for human use; in the process greatly expanding the protective abilities of the original antifreeze glycoprotein. While the natural glycoprotein only protects cells from low temperatures, Sirona Biochem's patented family of glycoproteins is being tested in multiple cells types to protect against additional stressed environments including oxidative stress, UV rays, cold temperatures and nutrient deprivation.

About Sirona Biochem

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona's compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona's laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information visit www.sironabiochem.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

For more information regarding this press release, contact:

Christopher Hopton

CFO

Sirona Biochem Corp.

Phone: 1.604.282.6064

Email: chopton@sironabiochem.com

(MORE TO FOLLOW) Dow Jones Newswires

May 20, 2014 07:45 ET (11:45 GMT)

Sirona Grant Stock Options

April 25, 2014, 7:01 p.m. EDT

VANCOUVER, BC , Apr 25, 2014 (Marketwired via COMTEX) -- Sirona Biochem Corp. CA:SBM -4.55% (otcqx:SRBCF) (frankfurt:ZSB) (the "Company") announces that is has granted incentive stock options under its stock option plan to a director and officer of the company for the purchase of 750,000 common shares of the Company at a price of $0.11 per share for a period of five years.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

FOR FURTHER INFORMATION PLEASE CONTACT:

For more information regarding this press release, contact: Christopher Hopton CFO Sirona Biochem Corp. Phone: 1.604.282.6064 Email: chopton@sironabiochem.com

SOURCE: Sirona Biochem Corp.

© 2014 Marketwire L.P. All rights reserved

Sirona Biochem Announces Collaboration With Magellan BioScience

Apr 23, 2014 09:38:00 (ET)

Sirona Biochem Announces Collaboration With Magellan BioScience

VANCOUVER, BC--(Marketwired - April 23, 2014) - Sirona Biochem Corp. (TSX VENTURE: SBM) (OTCQX: SRBCF) (FRANKFURT: ZSB) is pleased to announce a collaboration with Magellan BioScience Group, Inc. The goal of the collaboration is to prioritize technologies discovered or identified by Magellan BioScience which require Sirona Biochem's expertise in stabilization for safe and effective commercial applications. Target markets for potential applications include pharmaceutical, cosmetic, and over the counter (OTC) consumer packaged goods.

"Securing partnerships like this one with Magellan BioScience is integral to Sirona's long term success," states Neil Belenkie, CEO of Sirona Biochem. "Access to world class libraries of technology present us with unending targets for innovative science. Our shared focus on the oceans as leading resources for discovery is a key component of this partnership."

"With Magellan BioScience's expertise in small molecule discovery, stabilization of an active lead is critical for any commercial development of a product. Our partnership with Sirona Biochem and their expertise in stabilization brings an added synergy that directly benefits our clients," asserts Dr. John Cronan, President and CEO of Magellan BioScience Group, Inc.

About Sirona Biochem

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona's compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona's laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information visit www.sironabiochem.com.

About Magellan BioScience

Magellan BioScience Group, Inc. is an innovative discovery company pursuing untapped sources of chemical diversity and identifying lead candidates derived from microorganisms for the development of new chemical entities. With more than two decades of experience, Magellan has developed numerous proprietary media for the culture of marine microbes.

Magellan was founded in 1997 with the mission to provide a new source of microbial extracts for drug discovery, agrochemical, cosmetic, food/flavor, animal health care, and specialty chemical research. Based in Tampa, Florida, we develop symbiotic collaborations with research companies and academic centers around the world, to capitalize on the diversity and novelty of our natural product compounds in screens against a wide variety of therapeutic targets. Visit www.magellanbioscience.com for more information.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

For more information regarding this press release, contact:

Christopher Hopton

CFO

Sirona Biochem Corp.

Phone: 1.604.282.6064

Email: chopton@sironabiochem.com

(MORE TO FOLLOW) Dow Jones Newswires

April 23, 2014 09:38 ET (13:38 GMT)

Sirona Engages Torrey Hills Capital

Apr 17, 2014 07:45:00 (ET)

Sirona Engages Torrey Hills Capital

VANCOUVER, BC--(Marketwired - April 17, 2014) - Sirona Biochem Corp. (TSX VENTURE: SBM) (OTCQX: SRBCF) (FRANKFURT: ZSB), (the "Company") is pleased to announce that it has retained the services of San Diego Torrey Hills Capital, Inc. ("Torrey Hills "), a Rancho Santa Fe, California based investor relations firm, to provide market awareness and investor relations services to the Company, subject to TSX Venture Exchange acceptance. Torrey Hills will develop and manage a comprehensive finance and investor relations campaign for the Company including building and maintaining an investor audience, increasing awareness of the Company in the investor community and coordinating communication with management and investment professionals.

"Torrey Hills Capital brings a track record of success working with companies like Sirona Biochem. We are looking forward to their support in introducing and educating our target audiences about Sirona's unique value proposition," states Neil Belenkie, CEO of Sirona Biochem.

"We are excited to partner with Sirona Biochem," commented Cliff Mastricola, President of Torrey Hills Capital. "Management has a proven record of success and we really like what the Company is doing with its proprietary chemistry technology to enhance the stability of carbohydrate-based molecules. As a result, we believe the investment community will have an interest in the story."

In addition to the stock options described below, Torrey Hills, through its officers, directors, employees, and consultants, controls approximately twenty-five thousand common shares of stock of the Company, which were purchased on the open market.

Under the terms of the agreement, the Company will pay Torrey Hills US$4,000 per month for a period of six months and grant Torrey Hills 400,000 stock options for a period of three years at an exercise price of $0.16 per share, with vesting in accordance with TSX Venture Exchange policies and the Company's Stock Option Plan.

About San Diego Torrey Hills Capital

Torrey Hills Capital is a leading investor relations firm focused on introducing management teams and marketing small and microcap companies to investors in more than 50 cities across the United States and Canada. We organize one-on-one and group meetings between our clients and our network of institutional, retail, and private investors, as well as with analysts and newsletter writers. Our investors attend relevant industry conferences and participate in client site visits. Our comprehensive feedback and ongoing marketing efforts post-meetings are second to none.

About Sirona Biochem

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds' efficacy and safety. Sirona Biochem's compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem's wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

For more information regarding this press release, contact:

Christopher Hopton

CFO

Sirona Biochem Corp.

Phone: 1.604.282.6064

Email: chopton@sironabiochem.com

(MORE TO FOLLOW) Dow Jones Newswires

April 17, 2014 07:45 ET (11:45 GMT)

Sirona Biochem Announces Open Webinar for Q&A

Apr 03, 2014 07:45:00 (ET)

Sirona Biochem Announces Open Webinar for Q&A

VANCOUVER, BC--(Marketwired - April 03, 2014) - Sirona Biochem Corp. (TSX VENTURE: SBM) (OTCQX: SRBCF) (FRANKFURT: ZSB) is pleased to announce that it will be hosting a webinar to provide direct access to the leadership team of Sirona Biochem for questions and answers. The discussion will be moderated by Neil Belenkie, CEO of Sirona Biochem.

Details:

Date: Tuesday, April 15 2014

Time: 2pm - 3pm PDT

Register for Access: https://attendee.gotowebinar.com/register/4868347574215913729

About Sirona Biochem

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona's compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona's laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information visit www.sironabiochem.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

For more information regarding this press release, contact:

Christopher Hopton

CFO

Sirona Biochem Corp.

Phone: 1.604.282.6064

Email: chopton@sironabiochem.com

(MORE TO FOLLOW) Dow Jones Newswires

April 03, 2014 07:45 ET (11:45 GMT)

Sirona Biochem Announces Patent for Anti-Aging Family of Compounds

Apr 01, 2014 07:45:00 (ET)

Sirona Biochem Announces Patent for Anti-Aging Family of Compounds

VANCOUVER, BC--(Marketwired - April 01, 2014) - Sirona Biochem Corp. (TSX VENTURE: SBM.V) (OTCQX: SRBCF) (FRANKFURT: ZSB) is pleased to announce that a new patent application has been deposited by its subsidiary TFChem for a second generation of glycoprotein compounds. The first target marketplace for this technology will be anti-aging cosmetics. Future applications may include consumer packaged goods and prescription pharmaceuticals.

The Anti-Aging Project:

In the late 1960s Professor Arthur DeVries discovered that Antarctic fish were able to survive sub-zero temperatures under the polar icecaps thanks to glycoproteins that protect their cells.

Sirona and its subsidiary TFChem have successfully synthesized compounds derived from these naturally occurring glycoproteins and created an anti-aging technology intended to protect people's skin not just from cold temperatures but UV damage, oxidative stress and other catalysts of visible aging.

This project is also being championed by Jacques Cousteau's son and grandson, Jean-Michel and Fabien Cousteau, who will lend their names and global brand to support the commercialization of this new anti-aging cosmetic technology.

About Sirona Biochem

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona's compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona's laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information visit www.sironabiochem.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

For more information regarding this press release, contact:

Christopher Hopton

CFO

Sirona Biochem Corp.

Phone: 1.604.282.6064

Email: chopton@sironabiochem.com

(MORE TO FOLLOW) Dow Jones Newswires

April 01, 2014 07:45 ET (11:45 GMT)

Nice!!

Sirona Biochem Announces Jacques Cousteau's Son and Grandson as Brand Ambassadors

Mar 27, 2014 07:45:00 (ET)

Sirona Biochem Announces Jacques Cousteau's Son and Grandson as Brand Ambassadors

VANCOUVER, BC--(Marketwired - March 27, 2014) - Sirona Biochem Corp. (TSX VENTURE: SBM) (OTCQX: SRBCF) (FRANKFURT: ZSB) is pleased to announce that Jean-Michel Cousteau and Fabien Cousteau (son and grandson of Jacques Cousteau) will become Brand Ambassadors for the Company. A formal Brand Ambassador launch event has been scheduled for April 8, 2014 at TFChem in Val de Reuil, France.

As Brand Ambassadors for Sirona Biochem, Jean-Michel Cousteau and Fabien Cousteau will publicize our partnership's alliance and goals to industry experts, commercial partners and investors. Sirona Biochem will contribute its cosmetic, pharmaceutical and scientific expertise and Sirona will become a primary scientific resource for the potential commercialization of new ocean resources in collaboration with the Cousteaus. The Cousteaus and Sirona also share the goal of establishing a new accreditation for consumer packaged goods to validate technologies that are safe both for consumers and our fragile environments.

The launch event is scheduled to include a tour of the TFChem laboratory followed by a reception for attendees. Notable attendees are expected to include members of the French government, pharmaceutical and cosmetic industry leaders, and media representatives. This event is by invitation only.

About Sirona Biochem

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona's compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona's laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information visit www.sironabiochem.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

For more information regarding this press release, contact:

Christopher Hopton, CFO

Sirona Biochem Corp.

Phone: 1.604.282.6064

Email: chopton@sironabiochem.com

(MORE TO FOLLOW) Dow Jones Newswires

March 27, 2014 07:45 ET (11:45 GMT)

Sirona Biochem Welcomes Claude Nivet, New Laboratory Operations Manager at TFChem

6:55 PM ET 3/21/14 | Marketwire

Sirona Biochem Corp. (TSX VENTURE: SBM)(OTCQX: SRBCF)(FRANKFURT: ZSB) Sirona Biochem is pleased to announce that Claude Nivet has joined TFChem in the newly created position of Laboratory Operations Manager. Claude's responsibilities include leading the plan to expand TFChem's physical structure and scientific team.

Claude brings more than 30 years of experience working in pharmaceutical companies and will report directly to Dr. Geraldine Deliencourt-Godefroy. Claude will manage the daily operations of TFChem, enabling Dr. Deliencourt-Godefroy to focus on leading the scientific advancement of our proprietary technology and R&D pipeline.

"We are excited to have Claude join our team at TFChem," states Neil Belenkie, CEO of Sirona Biochem. "Claude has a proven track record leading laboratories through their growth strategies and he will create and manage the organizational structure required to support long term, efficient operations at TFChem."

About Sirona Biochem

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented and protected for maximum revenue potential.

Sirona's compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona's laboratory, TFChem (Rouen, France) is the recipient of multiple French national scientific awards and European Union and French government grants. For more information visit www.sironabiochem.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.



For more information regarding this press release, contact:
Christopher Hopton, CFO
Sirona Biochem Corp.
Phone:Â 1.604.282.6064
Email: chopton@sironabiochem.com




SOURCE: Sirona Biochem Corp.

mailto:chopton@sironabiochem.com

Nice!

Sirona Biochem Closes Private Placement

Mar 06, 2014 17:26:00 (ET)

Sirona Biochem Closes Private Placement

VANCOUVER, BC--(Marketwired - March 06, 2014) - Sirona Biochem Corp. (TSX-V: SBM) (OTCQX: SRBCF) (FRANKFURT: ZSB) (the "Company") is pleased to announce that it has closed its private placement in the amount of 9,230,770 units at $0.13 per unit for total gross proceeds of $1,200,000. Each unit consists of one common share and one transferable share purchase warrant, each warrant exercisable into one additional common share of the Company for a period of three years from the date of issue at a price of $0.20 per share.

Sirona would like to welcome the participation of leading hedge fund manager AlphaNorth Asset Management to our investor group.

The Company paid a total of $1,976 in cash and issued a total of 15,200 share purchase warrants to finders in connection with the placement. Each finder's warrant is exercisable into one common share of the Company for a period of three years at a price of $0.20 per share.

All securities issued under the placement are subject to statutory hold periods expiring on July 7, 2014.

Proceeds of the placement will be used for general working capital.

About Sirona Biochem

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds' efficacy and safety. Sirona Biochem's compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem's wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

For more information regarding this press release, contact:

Christopher Hopton, CFO

Sirona Biochem Corp

Phone: 604.282.6064

Email: chopton@sironabiochem.com

(END) Dow Jones Newswires

March 06, 2014 17:26 ET (22:26 GMT)

Thanks

I think its around 230M including all the warrants and options outstanding as well...

Bux it's just a matter of time.

Sirona Biochem Completes Global Exclusive Licensing Agreement with Obagi Medical Products

Jan 29, 2014 07:45:00 (ET)

Sirona Biochem Completes Global Exclusive Licensing Agreement with Obagi Medical Products

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jan 29, 2014) - Sirona Biochem Corp. (TSX VENTURE:SBM)(OTCQX:SRBCF)(FRANKFURT:ZSB) announced today the formal execution of the global exclusive licensing agreement with Obagi Medical Products (Obagi) for the commercialization of skin lightening compound TFC-849. Sirona Biochem will receive a licensing fee and ongoing royalty payments for global product sales from Obagi Medical Products.

Sirona will transfer its patented skin lightening technology and know-how to Obagi. Obagi will be responsible for the manufacturing, distribution and global sales of the final commercial products. Target launch of products including Sirona Biochem's TFC-849 is Q4 2014 for Obagi. The exclusive license for TFC-849 is valid for the global Valeant Pharmaceuticals family of companies.

"Obagi Medical Products is a premiere brand and provider of dermatological therapies worldwide," said Neil Belenkie, Chief Executive Officer of Sirona Biochem. "The skin lightening market, projected to reach $19.8 billion globally by 2018, provides an enormous commercial opportunity for both OMP and Sirona Biochem to provide safer, more effective therapies. We hope this is just the first of many opportunities to work with Obagi Medical Products and the Valeant Pharmaceutical family of companies."

About Obagi Medical Products

Obagi Medical Products, Inc. is a global specialty pharmaceutical company founded by leading skin care experts in 1988, and is owned by Valeant Pharmaceuticals International, Inc. Obagi products are designed to minimize the appearance of premature skin aging, skin damage, hyperpigmentation, acne, and sun damage and are primarily available through dermatologists, plastic surgeons, medical spas, and other skin care professionals.

About Sirona Biochem

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds' efficacy and safety. Sirona Biochem's compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem's wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com.

About the Betaclear (Skin Lightening) Project

Sirona Biochem's French subsidiary TFChem received a $1.9 million grant in November 2011. This project is co-financed by the European Union and Europe Witnesses in Haute-Normandie with the support of the European Regional Development Fund (E.R.D.F.). A consortium of partners, including the University of Rouen (LMSM EA4312), contract research organization Biogalenys, and TFChem has been assembled to advance this project. The French government and European Union are looking to promote and initiate collaborative projects that are focused on the development of new products and services containing a high level of innovation.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Forward-looking statements in many cases can be identified by words such as "may", "will", "expect", "believe", "potential" or other similar terms. Risks and uncertainties include, without limitation, negotiation of the terms of a definitive license agreement; difficulties or delays in development, testing and obtaining regulatory approval of a product; unexpected adverse side effects or inadequate therapeutic efficacy of a product that could delay or prevent product development or commercialization; the scope and validity of patent protection for a product; and competition from other companies. As a result, there are no assurances (i) that Obagi Medical Products will be able to develop and commercialize Sirona's skin lightening compound TFC-849; and (ii) that Sirona Biochem will be able to earn the milestone payments as contemplated under the agreement or that Obagi Medical Products will obtain sales of a product at reasonable commercial levels.

Readers are accordingly cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this news release. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

Sirona Biochem Corp.

Christopher Hopton

CFO

1.604.282.6064

chopton@sironabiochem.com

www.sironabiochem.com

(MORE TO FOLLOW) Dow Jones Newswires

January 29, 2014 07:45 ET (12:45 GMT)

Sirona Biochem Completes Exclusive Licensing Agreement With Leading Anti-Diabetic Company in China, Wanbang Biopharmaceuticals

Jan 27, 2014 07:45:00 (ET)

Sirona Biochem Completes Exclusive Licensing Agreement With Leading Anti-Diabetic Company in China, Wanbang Biopharmaceuticals

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jan 27, 2014) - Sirona Biochem Corp. (TSX VENTURE:SBM)(OTCQX:SRBCF) announced today the completion of an exclusive licensing agreement with Wanbang Biopharmaceuticals (Wanbang Biopharma). Sirona Biochem will provide an exclusive license to Wanbang Biopharma to develop and commercialize Sirona's anti-diabetic SGLT2 inhibitor in the People's Republic of China (PRC).In exchange for this license, Wanbang Biopharma will provide upfront and milestone payments of up to US$9.5M in addition to royalty payments for product sales in the PRC.

Details: In return for a robust licensing, milestone and royalty agreement, Sirona Biochem has transferred the responsibility for all funding, clinical development, regulatory requirements, manufacturing, sales and marketing of its SGLT2 inhibitor in China. Wanbang Biopharma will share all data generated through its clinical studies, significantly elevating the value of Sirona's SGLT2 inhibitor for licensing in the rest of the world. Recent transaction values for SGLT2 Inhibitors include:

-- Empagliflozin, one of a two-compound licensing deal between Boehringer
Ingelheim and Eli Lilly for at one time payment of EUR300 million and
milestone payments of EUR625 million.

-- Dapagliflozin (Forxiga(R)), one of a two-compound licensing deal between
Bristol Myers Squibb and AstraZeneca for upfront payment of US$100
million and milestone payments of up to US$1.25 billion

-- Bristol Myers Squibb and AstraZeneca expand licensing deal of
dapagliflozin to include Japan; deal estimated to bring more than US$1
billion
In China alone, more than 90 million people suffer from diabetes, and this number is increasing at an alarming rate of 20% per year.

"We are proud to work with Wanbang Biopharma in the continued development of our SGLT2 inhibitor as treatment for this global epidemic." said Neil Belenkie, Chief Executive Officer of Sirona Biochem.

About Wanbang Biopharma

Wanbang Biopharma is a leading pharmaceutical company in China that specializes in research, production and marketing of medicines for diabetes, cardiovascular disease and endocrinology. Among domestic pharmaceutical companies, Wanbang Biopharma is one of the largest manufacturers and marketers of a comprehensive portfolio of drugs for diabetes.

Wanbang Biopharma is a subsidiary of Fosun Pharmaceutical Group (Fosun Pharma) which is listed on the Shanghai stock exchange (600196.SH) and the Hong Kong stock exchange (02196.HK). Fosun Pharma is part of Fosun Group, the leading non-state owned enterprise group in China which is listed on the Hong Kong stock exchange (00656.HK).

About Sirona Biochem

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds' efficacy and safety. Sirona Biochem's compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem's wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com.

Sirona Biochem would like to thank Eyal Harel and Wang Pu of XinTech (Bio Sciences) for their invaluable contribution to this project. www.xintechnologies.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Forward-looking statements in many cases can be identified by words such as "may", "will", "expect", "believe", "potential" or other similar terms. Risks and uncertainties include, without limitation; difficulties or delays in development, testing and obtaining regulatory approval of a drug; unexpected adverse side effects or inadequate therapeutic efficacy of a drug that could delay or prevent product development or commercialization; the scope and validity of patent protection for a product; and competition from other pharmaceutical or biotechnology companies. As a result, there are no assurances (i) that Wanbang Pharma will be able to develop and commercialize Sirona's SGLT2 Inhibitor or obtain China's FDA approval of a drug; and (ii) that Sirona Biochem will be able to earn the milestone payments or Wanbang Pharma will obtain sales of a drug at reasonable commercial levels.

Readers are accordingly cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this news release. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

Sirona Biochem Corp.

Christopher Hopton

CFO

1.604.282.6064

chopton@sironabiochem.com

www.sironabiochem.com

(MORE TO FOLLOW) Dow Jones Newswires

January 27, 2014 07:45 ET (12:45 GMT)